News|Articles|June 12, 2024

Timothy Law: GLP-1 Drugs Changed the Paradigm in Weight Loss | AHIP 2024

In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about how GLP-1 agonist drugs like Wegovy and Zepbound are changing the paradigm for weight loss.

Drugs like Wegovy and Zepbound are not a panacea for those people looking for a quick fix, Timothy Law, DO, MBA, chief medical officer of Highmark Inc., said in an interview with Managed Healthcare Executive before the annual AHIP meeting in Las Vegas. Law — along with panelists Melanie R. Jay, M.D., director of NYU Langone Comprehensive Program on Obesity Research, and Amy Meister, D.O., chief medical officer of WeightWatchers, is speaking about how GLP-1 therapies are changing how the healthcare industry views prevention and treatment.

Highmark is an independent licensee of the Blue Cross Blue Shield Association about 7 million members in Pennsylvania, Delaware, New York and West Virginia.

Here Law talks about what GLP-1 agonist drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) can do and the important of lifestyle management

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.


Latest CME